Cigna Expands Coverage for Kerecis Fish-Skin Grafts
Cigna, one of the largest health insurers in the United States, has updated its medical coverage policy to include Kerecis fish-skin grafts for the treatment of diabetic foot ulcers. This change means that nearly 200 million Americans now have access to Kerecis products under commercial insurance plans that recognize fish-skin grafts as medically necessary for chronic wound care.
The coverage applies to patients whose diabetic foot ulcers have not responded adequately to conventional treatments and meet specific clinical criteria. Kerecis products, including the MariGen® and Shield® lines, are now available to tens of millions of additional Americans.
“Access is critical in improving outcomes in chronic wound care,” said Fertram Sigurjonsson, Founder and CEO of Kerecis. “We’re pleased that Cigna recognizes the clinical value of our technology, allowing more patients to benefit from regenerative fish skin as part of their treatment options.”
Kerecis develops sustainably sourced fish skin and fatty acid products for cellular therapy, tissue regeneration, and protection. Their patented material supports the body’s natural healing processes when grafted onto damaged human tissue. Clinical studies have shown that Kerecis products heal wounds faster than competitors.
This coverage expansion is a significant milestone for Kerecis, which is committed to the UN Sustainable Development Goals and uses renewable energy to process sustainably sourced Icelandic fish. The company is part of Coloplast, a leading supplier of intimate healthcare products.
For more information about Kerecis and its clinical research, visit www.kerecis.com.
